STELLA PHARMA CORPORATION (4888) AI Stock Analysis

• Market Cap: ¥13.68B
• Dividend Yield: N/A
• Average Volume (3M): 302.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 256.62%
• EPS Growth: 82.54%
• Country: JP
• Employees: 44
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -20.76
• Shares Outstanding: 34,034,100
• 10 Day Avg. Volume: 332,700
• 30 Day Avg. Volume: 302,970
• PEG Ratio: 10.60
• Price to Book (P/B): 4.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: ¥381.00 ▼(-5.22%Downside)

The stock score is primarily driven by strong revenue growth and a positive cash flow transition, which are promising signs of potential financial improvement. However, the negative valuation metrics, due to ongoing losses and lack of profitability, significantly weigh down the score. The technical indicators offer some optimism, suggesting a potential upward trend, but the overall score reflects the substantial risks associated with the current financial performance and valuation concerns.

STELLA PHARMA CORPORATION Business Overview & Revenue Model

Company Description

STELLA PHARMA CORPORATION (4888) is a pharmaceutical company focused on the research, development, and commercialization of innovative oncology therapies. The company specializes in creating advanced treatment solutions for cancer patients, aiming to improve patient outcomes through cutting-edge technology and scientific expertise.

How the Company Makes Money

STELLA PHARMA CORPORATION generates revenue through the sale of its proprietary oncology treatments and therapies to healthcare providers, hospitals, and clinics. The company invests heavily in research and development to bring new and effective cancer treatments to market. Additionally, STELLA PHARMA may engage in strategic partnerships and licensing agreements with other pharmaceutical companies to expand its product offerings and reach broader markets. Revenue is also likely derived from government grants or subsidies related to pharmaceutical innovations and contributions to public health.

STELLA PHARMA CORPORATION Financial Statement Overview

Summary

STELLA PHARMA CORPORATION has shown impressive revenue growth and a strong equity base, which are positive indicators. However, the persistent operational losses and negative profit margins are significant concerns. The shift to positive free cash flow suggests potential for improved financial health if operational efficiencies can be achieved.

Income Statement

The company has shown significant revenue growth over the years, with a remarkable increase from ¥100 million in 2022 to ¥961 million in 2025. However, the company is not profitable yet, as it continues to report negative net income and EBIT. Profit margins are negative, which is a concern as it indicates ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with Stockholders' Equity consistently higher than Total Debt, resulting in a low Debt-to-Equity ratio. The equity ratio is robust, reflecting a stable financial structure. However, the presence of high net losses could affect future equity levels if not addressed.

Cash Flow

The company has improved its cash flow position, transitioning from negative free cash flow in earlier years to positive free cash flow in 2025. Operating cash flow has also turned positive, which is a positive sign for operational efficiency. However, the ratio of operating cash flow to net income is low due to significant net losses.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
323.90M	961.06M	269.49M	229.07M	100.10M	205.97M
	Gross Profit
264.84M	811.03M	217.49M	206.94M	84.86M	181.78M
	EBIT
-669.23M	-90.25M	-760.30M	-806.77M	-741.90M	-680.57M
	EBITDA
-632.43M	-99.06M	-723.85M	-738.34M	-726.86M	-621.70M
	Net Income Common Stockholders
-667.95M	-140.81M	-763.75M	-778.82M	-767.72M	-659.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.45B	3.21B	2.35B	2.71B	3.28B	1.25B
	Total Assets
5.08B	5.42B	3.82B	4.33B	4.72B	2.05B
	Total Debt
813.00M	766.78M	933.30M	1.09B	1.25B	1.41B
	Net Debt
-2.64B	-2.44B	-1.12B	-1.62B	-2.02B	162.05M
	Total Liabilities
2.10B	2.21B	1.44B	1.58B	1.64B	1.82B
	Stockholders Equity
2.97B	3.21B	2.38B	2.75B	3.08B	230.72M
Cash Flow		Free Cash Flow
0.00	136.50M	-887.82M	-857.00M	-1.13B	-795.25M
	Operating Cash Flow
0.00	140.41M	-876.84M	-827.67M	-1.08B	-772.81M
	Investing Cash Flow
0.00	287.58M	-9.01M	-29.93M	-350.56M	-22.86M
	Financing Cash Flow
0.00	725.78M	228.35M	291.82M	3.83B	-332.40M

STELLA PHARMA CORPORATION Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 402.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4888, the sentiment is Positive. The current price of 402 is above the 20-day moving average (MA) of 367.40, above the 50-day MA of 340.88, and below the 200-day MA of 454.30, indicating a neutral trend. The MACD of 14.11 indicates Negative momentum. The RSI at 64.50 is Neutral, neither overbought nor oversold. The STOCH value of 80.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4888.

STELLA PHARMA CORPORATION Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	68 Neutral	¥14.42B	284.55		0.69%	-13.57%	-106.11%
4579	62 Neutral	¥15.24B	―		―	57.13%	-66.39%
4888	55 Neutral	¥13.68B	―		―	256.62%	82.54%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
4583	48 Neutral	¥11.16B	―		―	14.41%	27.42%
4599	47 Neutral	¥19.88B	―		―	-100.00%	-1079.89%
4588	44 Neutral	¥15.43B	―		―	11.93%	15.04%